Drug Repurposing for Monkeypox: An Alternative Strategy for Emergency Response

Luthfi Harbulcholizi, Jekmal Malau, Ihsan Alfiandri, Iqbal Zulkifli, Ratika Rahmasari

Abstract

The global monkeypox (MPOX) outbreak, which has resulted in more than 100,000 confirmed cases across over 120 countries, underscores the urgent need for effective therapeutic strategies. MPOX, caused by a virus belonging to the Orthopoxvirus genus, poses significant clinical and public health challenges, particularly in regions with limited healthcare capacity. Although the World Health Organization declared MPOX a Public Health Emergency of International Concern in 2022, no specific antiviral treatment has yet been formally approved for use. While vaccination remains essential for long-term prevention, its impact is limited by the constraints of limited availability and unequal global distribution. Consequently, drug repurposing has emerged as a practical, rapid, and cost-efficient strategy to address immediate therapeutic demands during active outbreaks. This narrative review evaluates key repurposed antiviral agents, including tecovirimat, brincidofovir, and cidofovir, which were originally developed for other Orthopoxvirus infections. A structured literature search using PubMed, ScienceDirect, and Google Scholar (2014–2024) identified studies providing clinically relevant evidence regarding their therapeutic roles in MPOX. Tecovirimat demonstrated consistent potential to improve viral clearance, shorten symptom duration, and reduce severe manifestations. Brincidofovir exhibited a more favorable safety profile, albeit with limited clinical data, whereas cidofovir showed antiviral activity but remains restricted by its nephrotoxicity. Collectively, current evidence suggests that drug repurposing offers a timely and resource-efficient option for managing MPOX and mitigating disease burden while vaccine accessibility continues to vary globally. When integrated with targeted public health interventions, repurposed drugs may serve as a crucial interim strategy to reduce transmission and enhance outbreak response capacity.

Keywords

Antiviral Agents; Brincidofovir; Cidofovir; Drug Repurposing; Monkeypox; Tecovirimat

References

Abdelghany, A. M., Ghaly, F. F., & Allam, M. F. (2024). Antiviral Drugs for Treatment of Human Monkeypox: A Systematic Review/Meta-analysis. Microbes, Infection and Chemotherapy, 4, e1963. https://doi.org/10.54034/mic.e1963

Agrawal, P. (2015). Advantages and Challenges in Drug Re-Profiling. Journal of Pharmacovigilance, s2. https://doi.org/10.4172/2329-6887.s2-e002

Akiyama, Y., Morioka, S., Tsuzuki, S., Yoshikawa, T., Yamato, M., Nakamura, H., Shimojima, M., Takakusaki, M., Saito, S., Takahashi, K., Sanada, M., Komatsubara, M., Takebuchi, K., Yamaguchi, E., Suzuki, T., Shimokawa, K., Kurosu, T., Kawahara, M., Oishi, K., … Ohmagari, N. (2024). Efficacy and viral dynamics of tecovirimat in patients with MPOX: A multicenter open-label, double-arm trial in Japan. Journal of Infection and Chemotherapy, 30(6), 488–493. https://doi.org/10.1016/j.jiac.2023.11.025

Alakunle, E., Kolawole, D., Diaz-Cánova, D., Alele, F., Adegboye, O., Moens, U., & Okeke, M. I. (2024). A comprehensive review of monkeypox virus and mpox characteristics. In Frontiers in Cellular and Infection Microbiology (Vol. 14). Frontiers Media SA. https://doi.org/10.3389/fcimb.2024.1360586

Alameer, R. M., Yamani, A., Al-Saud, A., Alsobayeg, S., Alamro, B., Alali, A., Hammad, E., Shendi, A. M., & Almaghrabi, R. S. (2024). The successful treatment of mpox with brincidofovir in renal transplant recipients—a report of 2 cases. International Journal of Infectious Diseases, 143. https://doi.org/10.1016/j.ijid.2024.107015

Aljabali, A. A., Obeid, M. A., Nusair, M. B., Hmedat, A., & Tambuwala, M. M. (2022). Monkeypox virus: An emerging epidemic. In Microbial Pathogenesis (Vol. 173). Academic Press. https://doi.org/10.1016/j.micpath.2022.105794

Amer, F., Khalifa, H. E. S., Elahmady, M., ElBadawy, N. E., Zahran, W. A., Abdelnasser, M., Rodríguez-Morales, A. J., Wegdan, A. A., & Tash, R. M. E. (2023). Mpox: Risks and approaches to prevention. In Journal of Infection and Public Health (Vol. 16, Issue 6, pp. 901–910). Elsevier Ltd. https://doi.org/10.1016/j.jiph.2023.04.001

Andrei, G., Topalis, D., De Schutter, T., & Snoeck, R. (2015). Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia. Antiviral Research, 114, 21–46. https://doi.org/https://doi.org/10.1016/j.antiviral.2014.10.012

Awoyomi, O. J., Njoga, E. O., Jaja, I. F., Oyeleye, F. A., Awoyomi, P. O., Ibrahim, M. A., Saulawa, M. A., Galadima, H. B., Rowaiye, A. B., Olasoju, T. I., Idrisa, J. A., Olalere, F. D. H., Olasoju, M. I., Adisa, O. H., Adetunji, V. E., Idemudia, O. O., Ezenduka, E. V., & Oguttu, J. W. (2023). Mpox in Nigeria: Perceptions and knowledge of the disease among critical stakeholders—Global public health consequences. PLoS ONE, 18(3). https://doi.org/10.1371/journal.pone.0283571

Azvolinsky, A. (2017). Repurposing existing drugs for new indications. The Scientist.

Beaucourt, S., & Vignuzzi, M. (2014). Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Current opinion in virology, 8, 10–15. https://doi.org/10.1016/j.coviro.2014.04.011

Bhardwaj, P., Sarkar, S., & Mishra, R. (2024). Mpox and related poxviruses: A literature review of evolution, pathophysiology, and clinical manifestations. Asian Pacific Journal of Tropical Biomedicine, 14(8), 319-330. https://doi.org/10.4103/apjtb.apjtb_193_24

Branda, F., Romano, C., Ciccozzi, M., Giovanetti, M., Scarpa, F., Ciccozzi, A., & Maruotti, A. (2024). Mpox: an overview of pathogenesis, diagnosis, and public health implications. Journal of Clinical Medicine, 13(8), 2234.

Breman, J. G., & Henderson, D. A. (2002). Diagnosis and management of smallpox. New England Journal of Medicine, 346(17), 1300-1308.

Butic, A. B., Katz, Z. E., Jin, G., Fukushima, K., Hazama, M., Lukacher, A. E., & Lauver, M. D. (2024). Brincidofovir inhibits polyomavirus infection in vivo. MBio, 15(8). https://doi.org/10.1128/mbio.01049-24

Byrareddy, S. N., Sharma, K., Sachdev, S., Reddy, A. S., Acharya, A., Klaustermeier, K. M., ... & Singh, K. (2023). Potential therapeutic targets for Mpox: the evidence to date. Expert Opinion on Therapeutic Targets, 27(6), 419-431.

Chakravarty, N., Hemani, D., Paravastu, R., Ahmad, Z., Palani, S. N., Arumugaswami, V., & Kumar, A. (2024). Mpox Virus and its ocular surface manifestations. Ocular Surface, 34, 108–121. https://doi.org/10.1016/j.jtos.2024.07.001

Chamberlain, J. M., Sortino, K., Sethna, P., Bae, A., Lanier, R., Bambara, R. A., & Dewhurst, S. (2018). Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus. Antimicrobial agents and chemotherapy, 63(1), e01925-18. https://doi.org/10.1128/AAC.01925-18

DeLaurentis, C. E., Kiser, J., & Zucker, J. (2022). New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus. Antimicrobial Agents and Chemotherapy 66(12), e0122622. https://doi.org/10.1128/aac.01226-22

Duarte, P. M., Adesola, R. O., Priyadarsini, S., Singh, R., Shaheen, M. N. F., Ogundijo, O. A., Gulumbe, B. H., Lounis, M., Samir, M., Govindan, K., Adebiyi, O. S., Scott, G. Y., Ahmadi, P., Mahmoodi, V., Chogan, H., Gholami, S., Shirazi, O., Moghadam, S. K., Jafari, N., … Tazerji, S. S. (2024). Unveiling the Global Surge of Mpox (Monkeypox): A comprehensive review of current evidence. The Microbe, 4, 100141. https://doi.org/10.1016/j.microb.2024.100141

Ekpunobi, N., Akinsuyi, O., Ariri, T., & Ogunmola, T. (2023). The Reemergence of Monkeypox in Nigeria. Challenges, 14(2), 22. https://doi.org/10.3390/challe14020022

Estévez, S., Vara, M., Gamo, M., Manzano, S., Troya, J., Botezat, E., Jiménez, E., Pedrero-Tomé, R., Martin, M. Á., de la Cueva, P., Fernández, E., Fernández, B., Brown, D. E., Palma, E., & Simón, A. (2023). Epidemiological and Clinical Characteristics of Patients Admitted to a Secondary Hospital with Suspected MPOX Virus Infection: Is HIV Playing a Role? Journal of Clinical Medicine, 12(12). https://doi.org/10.3390/jcm12124124

Everts, M., Cihlar, T., Bostwick, J. R., & Whitley, R. J. (2017). Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. Annual Review of Pharmacology and Toxicology, 57, 155–169. https://doi.org/10.1146/annurev-pharmtox-010716-104533

Ezat, A. A., Abduljalil, J. M., Elghareib, A. M., Samir, A., & Elfiky, A. A. (2023). The discovery of novel antivirals for the treatment of mpox: is drug repurposing the answer? In Expert Opinion on Drug Discovery, 18(5), 551–561. https://doi.org/10.1080/17460441.2023.2199980

Fang, P., Fang, L., Zhang, H., Xia, S., & Xiao, S. (2021). Functions of coronavirus accessory proteins: overview of the state of the art. Viruses, 13(6), 1139.

Faure, E., Galperine, T., Cannesson, O., Alain, S., Gnemmi, V., Goeminne, C., Dewilde, A., Béné, J., Lasri, M., De Sainte Foy, C. L., & Lionet, A. (2016). Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection. Medicine, 95(44), e5526. https://doi.org/10.1097/MD.0000000000005226

Gao, L., Shi, Q., Dong, X., Wang, M., Liu, Z., & Li, Z. (2023). Mpox, Caused by the MPXV of the Clade IIb Lineage, Goes Global. Tropical Medicine and Infectious Disease, 8(2), 76. https://doi.org/10.3390/tropicalmed8020076

Ghaseminia, M. (2023). Preventing monkeypox outbreaks: Focus on diagnosis, care, treatment, and vaccination. Journal of Clinical and Translational Science, 7(1), e11. https://doi.org/10.1017/cts.2023.11

Gu, C., Huang, Z., Sun, Y., Shi, S., Li, X., Li, N., Liu, Y., Guo, Z., Jin, N., Zhao, Z., Li, X., & Wang, H. (2024). Characterization of Human Immortalized Keratinocyte Cells Infected by Monkeypox Virus. Viruses, 16(8), 1206. https://doi.org/10.3390/v16081206

Harapan, H., Ophinni, Y., Megawati, D., Frediansyah, A., Mamada, S. S., Salampe, M., ... & Sallam, M. (2022). Monkeypox: a comprehensive review. Viruses, 14(10), 2155.

He, P., Shi, D., Li, Y., Xia, K., Kim, S. B., Dwivedi, R., Farrag, M., Pomin, V. H., Linhardt, R. J., Dordick, J. S., & Zhang, F. (2023). SPR Sensor-Based Analysis of the Inhibition of Marine Sulfated Glycans on Interactions between Monkeypox Virus Proteins and Glycosaminoglycans. Marine Drugs, 21(5), 264. https://doi.org/10.3390/md21050264

Hermanussen, L., Brehm, T. T., Wolf, T., Boesecke, C., Schlabe, S., Borgans, F., Monin, M. B., Jensen, B. E. O., Windhaber, S., Scholten, S., Jordan, S., Lütgehetmann, M., Wiesch, J. S. zur, Addo, M. M., Mikolajewska, A., Niebank, M., & Schmiedel, S. (2023). Tecovirimat for the treatment of severe Mpox in Germany. Infection, 51(5), 1563–1568. https://doi.org/10.1007/s15010-023-02049-0

Hernaez, B., & Alcamí, A. (2024). Poxvirus Immune Evasion. Annual Review of Immunology, 42, 551-584. https://doi.org/10.1146/annurev-immunol-090222

Huang, Y., Mu, L., & Wang, W. (2022). Monkeypox: epidemiology, pathogenesis, treatment and prevention. Signal Transduction and Targeted Therapy, 7,(1), 373. https://doi.org/10.1038/s41392-022-01215-4

Hudu, S. A., Alshrari, A. S., Al Qtaitat, A., & Imran, M. (2023). VP37 Protein Inhibitors for Mpox Treatment: Highlights on Recent Advances, Patent Literature, and Future Directions. Biomedicines, 11(4), 1106. https://doi.org/10.3390/biomedicines11041106

Israeli, O., Guedj-Dana, Y., Shifman, O., Lazar, S., Cohen-Gihon, I., Amit, S., Ben-Ami, R., Paran, N., Schuster, O., Weiss, S., Zvi, A., & Beth-Din, A. (2022). Rapid Amplicon Nanopore Sequencing (RANS) for the Differential Diagnosis of Monkeypox Virus and Other Vesicle-Forming Pathogens. Viruses, 14(8). https://doi.org/10.3390/v14081817

Ježek, Z., Szczeniowski, M., Paluku, K. M., & Mutombo, M. (1987). Human Monkeypox: Clinical Features of 282 Patients. The Journal of Infectious Diseases, 156(2), 293-299. https://doi.org/10.1093/infdis/156.2.293.

Kang, Y., & Ahmad, S. (2023). The emerging epidemics in recent: mpox. Life Cycle, 3. https://doi.org/10.54724/lc.2023.e3

Karagoz, A., Tombuloglu, H., Alsaeed, M., Tombuloglu, G., AlRubaish, A. A., Mahmoud, A., Smajlović, S., Ćordić, S., Rabaan, A. A., & Alsuhaimi, E. (2023). Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis. Journal of Infection and Public Health, 16(4), 531-541. https://doi.org/10.1016/j.jiph.2023.02.003

Kavey, R.-E., & Kavey, A. (2024). Viral Pandemics: From Smallpox to COVID-19 & Mpox. Routledge/Taylor & Francis Group. https://doi.org/10.4324/9781003427667

Lagi, F., Formica, G., Rostagno, A., Milia, A., Pradella, S., Guazzini, G., Tekle Kiros, S., Corsi, P., Bartoloni, A., Zammarchi, L., & Pieralli, F. (2024). When it rains, it pours: Early treatment with tecovirimat of cardiac complications associated with monkeypox infection in a person with HIV and previously undiagnosed Lyme disease. A case report. Heliyon, 10(1), e23965. https://doi.org/10.1016/j.heliyon.2023.e23965

Lee, W., Kim, Y. J., Lee, S. J., Ahn, D. G., & Kim, S. J. (2023). Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-Emerging Human Monkeypox Virus. Journal of Microbiology and Biotechnology, 33(8), 981–991. https://doi.org/10.4014/jmb.2306.06033

Li, E., Guo, X., Hong, D., Gong, Q., Xie, W., Li, T., Wang, J., Chuai, X., & Chiu, S. (2023). Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus. Signal Transduction and Targeted Therapy, 8(1), 350. https://doi.org/10.1038/s41392-023-01574-6

Li, M., Ren, Z., Wang, Y., Jiang, Y., Yang, M., Li, D., Chen, J., Liang, Z., Lin, Y., Zeng, Z., Xu, R., Wang, Y., Zhu, L., Xiao, W., Wu, Q., Zhang, B., Wan, C., Yang, Y., Wu, B., … Shen, C. (2023). Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus. Emerging Microbes and Infections, 12(2). https://doi.org/10.1080/22221751.2023.2223669

Lu, J., Xing, H., Wang, C., Tang, M., Wu, C., Ye, F., Yin, L., Yang, Y., Tan, W., & Shen, L. (2023). Mpox (formerly monkeypox): pathogenesis, prevention, and treatment. Signal Transduction and Targeted Therapy, 8(1), 458. https://doi.org/10.1038/s41392-023-01675-2

Majewska, A., Młynarczyk-Bonikowska, B., Malejczyk, M., Majewski, S., & Młynarczyk, G. (2019). Possibilities Of Prevention And Treatment Of Human Cytomegalovirus Infections Including New Drugs And Compounds With Potential Application. Postępy Mikrobiologii - Advancements of Microbiology, 58(3), 291–299. https://doi.org/10.21307/pm-2019.58.3.291

Malik, S., Ahmad, T., Ahsan, O., Muhammad, K., & Waheed, Y. (2023). Recent Developments in Mpox Prevention and Treatment Options. Vaccines, 11(3), 500. https://doi.org/10.3390/vaccines11030500

Marisah, M., Hilmi, I.L., & Salman, S. (2022). Studi Dan Tatalaksana Terkait Penyakit Cacar Monyet (Monkeypox) Yang Menginfeksi Manusia. Jurnal Farmasetis, 11(3), 201-208.

Martinez, A. E., Frattaroli, P., Vu, C. A., Paniagua, L., Mintz, J., Bravo-Gonzalez, A., Zamudio, P., Barco, A., Rampersad, A., Lichtenberger, P., & Gonzales-Zamora, J. A. (2023). Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report. Vaccines, 11(3), 650. https://doi.org/10.3390/vaccines11030650

Martínez-Fernández, D. E., Fernández-Quezada, D., Casillas-Muñoz, F. A. G., Carrillo-Ballesteros, F. J., Ortega-Prieto, A. M., Jimenez-Guardeño, J. M., & Regla-Nava, J. A. (2023). Human Monkeypox: A Comprehensive Overview of Epidemiology, Pathogenesis, Diagnosis, Treatment, and Prevention Strategies. Pathogens, 12(7), 947. https://doi.org/10.3390/pathogens12070947

Mitjà, O., Alemany, A., Marks, M., Lezama Mora, J. I., Rodríguez-Aldama, J. C., Torres Silva, M. S., Corral Herrera, E. A., Crabtree-Ramirez, B., Blanco, J. L., Girometti, N., Mazzotta, V., Hazra, A., Silva, M., Montenegro-Idrogo, J. J., Gebo, K., Ghosn, J., Peña Vázquez, M. F., Matos Prado, E., Unigwe, U., … Villareal, D. (2023). Mpox in people with advanced HIV infection: a global case series. The Lancet, 401(10380), 939–949. https://doi.org/10.1016/S0140-6736(23)00273-8

Monzón, S., Varona, S., Negredo, A., Vidal-Freire, S., Patiño-Galindo, J. A., Ferressini-Gerpe, N., Zaballos, A., Orviz, E., Ayerdi, O., Muñoz-Gómez, A., Delgado-Iribarren, A., Estrada, V., García, C., Molero, F., Sánchez-Mora, P., Torres, M., Vázquez, A., Galán, J. C., Torres, I., … Palacios, G. (2024). Monkeypox virus genomic accordion strategies. Nature Communications, 15(1), 3059. https://doi.org/10.1038/s41467-024-46949-7

Mucker, E. M., Freyn, A. W., Bixler, S. L., Cizmeci, D., Atyeo, C., Earl, P. L., Natarajan, H., Santos, G., Frey, T. R., Levin, R. H., Meni, A., Arunkumar, G. A., Stadlbauer, D., Jorquera, P. A., Bennett, H., Johnson, J. C., Hardcastle, K., Americo, J. L., Cotter, C. A., … Hooper, J. W. (2024). Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell, 187(23), 5540-5553. https://doi.org/10.1016/j.cell.2024.08.043

Musuka, G., Moyo, E., Tungwarara, N., Mhango, M., Pierre, G., Saramba, E., Iradukunda, P. G., & Dzinamarira, T. (2024). A critical review of mpox outbreaks, risk factors, and prevention efforts in Africa: Lessons learned and evolving practices. IJID Regions, 12, 100402. https://doi.org/10.1016/j.ijregi.2024.100402

Natami, M., Gorgzadeh, A., Gholipour, A., Fatemi, S. N., Firouzeh, N., Zokaei, M., Mohammed Ali, S. H., Kheradjoo, H., Sedighi, S., Gholizadeh, O., & Kalavi, S. (2024). An overview on mRNA-based vaccines to prevent monkeypox infection. Journal of Nanobiotechnology, 22(1), 86. https://doi.org/10.1186/s12951-024-02355-1

Nguyen, B. T., Marc, A., Suñer, C., Marks, M., Ubals, M., Hernández-Rodríguez, Á., Melendez, M. Á., Hruby, D. E., Russo, A. T., Mentré, F., Mitjà, O., Grosenbach, D. W., & Guedj, J. (2023). Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection. PLoS Biology, 21(12). https://doi.org/10.1371/journal.pbio.3002249

Oiwoh, S. O., Ibekwe, P. U., Ajani, A. A., Cole-Adeife, O. M., Olanrewaju, F. O., Oripelaye, M. M., Akinboro, A. O., Akinkugbe, A. O., & Mohammed, T. T. (2023). Systemic and Dermatologic Impact of Mpox Systemic and Dermatologic Impact of Mpox: An Overview of Guideline-Based Management for Nigerian Healthcare Workers. Niger Med J, 64(1), 4-12.

Parnian, R., Heydarifard, F., Mousavi, F. S., Heydarifard, Z., & Zandi, M. (2024). Innate Immune Response to Monkeypox Virus Infection: Mechanisms and Immune Escape. Journal of innate immunity, 16(1), 413–424. https://doi.org/10.1159/000540815

Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019). Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discovery Today, 24(10), 2076–2085. https://doi.org/10.1016/j.drudis.2019.06.014

Peng, Q., Xie, Y., Kuai, L., Wang, H., Qi, J., Gao, G. F., & Shi, Y. (2023). Structure of monkeypox virus DNA polymerase holoenzyme. Science, 379(6627), 100–105. https://doi.org/10.1126/science.ade6360

Petersen, E., Kantele, A., Koopmans, M., Asogun, D., Yinka-Ogunleye, A., Ihekweazu, C., & Zumla, A. (2019). Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infectious Disease Clinics of North America, 33(4), 1027–1043. https://doi.org/10.1016/j.idc.2019.03.001

Pittman, P. R., Hahn, M., Lee, H. S., Koca, C., Samy, N., Schmidt, D., Hornung, J., Weidenthaler, H., Heery, C. R., Meyer, T. P. H., Silbernagl, G., Maclennan, J., & Chaplin, P. (2019). Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. New England Journal of Medicine, 381(20), 1897–1908. https://doi.org/10.1056/nejmoa1817307

Prévost, J., Sloan, A., Deschambault, Y., Tailor, N., Tierney, K., Azaransky, K., Kammanadiminti, S., Barker, D., Kodihalli, S., & Safronetz, D. (2024). Treatment efficacy of cidofovir and brincidofovir against clade II Monkeypox virus isolates. Antiviral Research, 231. https://doi.org/10.1016/j.antiviral.2024.105995

Rabaan, A. A., Abas, A. H., Tallei, T. E., Al-Zaher, M. A., Al-Sheef, N. M., Fatimawali, Al-Nass, E. Z., Al-Ebrahim, E. A., Effendi, Y., Idroes, R., Alhabib, M. F., Al-Fheid, H. A., Adam, A. A., & Bin Emran, T. (2023). Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies. Journal of Medical Virology, 95(1), e28306. https://doi.org/10.1002/jmv.28306

Reynolds, M. G., McCollum, A. M., Nguete, B., Lushima, R. S., & Petersen, B. W. (2017). Improving the care and treatment of monkeypox patients in low-resource settings: Applying evidence from contemporary biomedical and smallpox biodefense research. Viruses, 9(12), 380. https://doi.org/10.3390/v9120380

Rizk, J. G., Lippi, G., Henry, B. M., Forthal, D. N., & Rizk, Y. (2022). Prevention and Treatment of Monkeypox. Drugs, 82(9), 957–963. https://doi.org/10.1007/s40265-022-01742-y

Russo, A. T., Grosenbach, D. W., Brasel, T. L., Baker, R. O., Cawthon, A. G., Reynolds, E., Bailey, T., Kuehl, P. J., Sugita, V., Agans, K., & Hruby, D. E. (2018). Effects of treatment delay on efficacy of tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques. Journal of Infectious Diseases, 218(9), 1490–1499. https://doi.org/10.1093/infdis/jiy326

Russo, A. T., Grosenbach, D. W., Honeychurch, K. M., Long, P. G., & Hruby, D. E. (2023). Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential. Expert Review of Anti-Infective Therapy, 21(3), 235–242. https://doi.org/10.1080/14787210.2023.2170350

Saadh, M. J., Ghadimkhani, T., Soltani, N., Abbassioun, A., Daniel Cosme Pecho, R., taha, A., Jwad Kazem, T., Yasamineh, S., & Gholizadeh, O. (2023). Progress and prospects on vaccine development against monkeypox infection. Microbial Pathogenesis, 180, 106156. https://doi.org/10.1016/j.micpath.2023.106156

Saied, A. A., Chandran, D., Chakraborty, S., Emran, T. Bin, & Dhama, K. (2023). Mpox and healthcare workers — a minireview of our present knowledge. The Egyptian Journal of Internal Medicine, 35(1), 46. https://doi.org/10.1186/s43162-023-00233-0

Saul, S., & Einav, S. (2020). Old drugs for a new virus: Repurposed approaches for combating covid-19. ACS Infectious Diseases, 6(9), 2304–2318. https://doi.org/10.1021/ACSINFECDIS.0C00343

Schmitt, A., Mätz-Rensing, K., & Kaup, F. J. (2014). Non-human primate models of orthopoxvirus infections. Veterinary Sciences, 1(1), 40–62. https://doi.org/10.3390/vetsci1010040

Schuele, L., Boter, M., Nieuwenhuijse, D. F., Götz, H., Fanoy, E., de Vries, H., Vieyra, B., Bavalia, R., Hoornenborg, E., Molenkamp, R., Jonges, M., van den Ouden, A., Simões, M., van den Lubben, M., Koopmans, M., Welkers, M. R. A., & Oude Munnink, B. B. (2024). Circulation, viral diversity and genomic rearrangement in mpox virus in the Netherlands during the 2022 outbreak and beyond. Journal of Medical Virology, 96(1), e29397. https://doi.org/10.1002/jmv.29397

Shchelkunov, S. N., Totmenin, A. V., Safronov, P. F., Mikheev, M. V., Gutorov, V. V., Ryazankina, O. I., Petrov, N. A., Babkin, I. V., Uvarova, E. A., Sandakhchiev, L. S., Sisler, J. R., Esposito, J. J., Damon, I. K., Jahrling, P. B., & Moss, B. (2002). Analysis of the monkeypox virus genome. Virology, 297(2), 172–194. https://doi.org/10.1006/viro.2002.1446

Shehryar, A., Halappa Nagaraj, R., Kanwal, F., Reddy, S. M., Grezenko, H., Raut, Y., Fareed, M. U., . A. R., Şahin, D., Bakht, D., & Ramteke, P. (2023). Unraveling Monkeypox: An Emerging Threat in Global Health. Cureus, 15(8), e43961. https://doi.org/10.7759/cureus.43961

Shishkina, L. N., Mazurkov, O. Y., Bormotov, N. I., Skarnovich, M. O., Serova, O. A., Mazurkova, N. A., Skarnovich, M. A., Chernonosov, A. A., Selivanov, B. A., Tikhonov, A. Y., Gamaley, S. G., Shimina, G. G., Sysoyeva, G. M., Taranov, O. S., Danilenko, E. D., Agafonov, A. P., & Maksyutov, R. A. (2023). Safety and Pharmacokinetics of the Substance of the Anti-Smallpox Drug NIOCH-14 after Oral Administration to Laboratory Animals. Viruses, 15(1), 205. https://doi.org/10.3390/v15010205

Siegrist, E. A., & Sassine, J. (2023). Antivirals With Activity Against Mpox: A Clinically Oriented Review. Clinical Infectious Diseases, 76(1), 155–164. https://doi.org/10.1093/cid/ciac622

Sobral-Costas, T. G., Escudero-Tornero, R., Servera-Negre, G., Bernardino, J. I., Arroyo, A. G., Díaz-Menéndez, M., ... & Cudos, E. S. (2023). Human monkeypox outbreak: epidemiological data and therapeutic potential of topical cidofovir in a prospective cohort study. Journal of the American Academy of Dermatology, 88(5), 1074-1082.

Sofiani, V. H., Rukerd, M. R. Z., Charostad, J., Pardeshenas, M., Ghazi, R., Arefinia, N., ... & Nakhaie, M. (2024). From Entry to Evasion: A Comprehensive Analysis of Host-Virus Interactions for Monkeypox. Infectious Microbes & Diseases, 6(2), 56-64. https://doi.org/10.1097/IM9.0000000000000146

Sultana, J., Crisafulli, S., Gabbay, F., Lynn, E., Shakir, S., & Trifirò, G. (2020). Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Frontiers in Pharmacology, 11, 588654. https://doi.org/10.3389/fphar.2020.588654

Ullah, M., Li, Y., Munib, K., & Zhang, Z. (2023). Epidemiology, host range, and associated risk factors of monkeypox: an emerging global public health threat. Frontiers in Microbiology, 14, 1160984. https://doi.org/10.3389/fmicb.2023.1160984

Wang, J., Shahed-AI-Mahmud, M., Chen, A., Li, K., Tan, H., & Joyce, R. (2023). An overview of antivirals against monkeypox virus and other orthopoxviruses. Journal of Medicinal Chemistry, 66(7), 4468-4490. https://doi.org/10.1021/acs.jmedchem.2c01811

Wang, Y., Zhang, Y. X., Liang, X. Y., Liu, Y. F., Gao, W., Yuan, H., ... & Wu, D. (2023). The Neglected Mpox Virus: From Historical Review to Future Perspectives. Authorea. https://doi.org/10.22541/au.168072935.33415959/v1

Wang, X., Gu, Z., Sheng, S., Song, R., & Jin, R. (2024). The Current State and Progress of Mpox Vaccine Research. China CDC weekly, 6(7), 118–125. https://doi.org/10.46234/ccdcw2024.025.

World Health Organization. (n.d). Clinical management of monkeypox. https://www.who.int/teams/health-care-readiness/clinical-management-of-monkeypox

World Health Organization. (2022). WHO Director-General declares the ongoing monkeypox outbreak a Public Health Event of International Concern. https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern

World Health Organization. (2024). Monkeypox global dashboard. Retrieved October 5, 2024, from https://worldhealthorg.shinyapps.io/mpx_global/

Yu, X., Shi, H., & Cheng, G. (2023). Mpox Virus: Its Molecular Evolution and Potential Impact on Viral Epidemiology. In Viruses, 15(4), 995. https://doi.org/10.3390/v15040995

Zinnah, M. A., Uddin, M. B., Hasan, T., Das, S., Khatun, F., Hasan, M. H., Udonsom, R., Rahman, M. M., & Ashour, H. M. (2024). The Re-Emergence of Mpox: Old Illness, Modern Challenges. Biomedicines, 12(7), 1457. https://doi.org/10.3390/biomedicines12071457

Zovi, A., Ferrara, F., Langella, R., & Vitiello, A. (2022). Pharmacological Agents with Antiviral Activity against Monkeypox Infection. International Journal of Molecular Sciences, 23(24), 15941. https://doi.org/10.3390/ijms232415941

DOI: https://doi.org/10.20961/jpscr.v10i3.96215

Refbacks

  • There are currently no refbacks.